Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
ARY News Live15h
VYLOY: Astellas’ gastric cancer therapy approved in US
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...
The Pharma Letter11h
FDA approves Astellas’ Vyloy
The US Food and Drug Administration has approved Vyloy (zolbetuximab-clzb), a claudin 18.2 (CLDN18.2)-directed cytolytic ...
The New York Times20h
Russia News
Natalia Morari once reported on corrupt business in Moldova. Now she has upset many by having a son with a tycoon accused of corruption, and running against the pro-West president in elections ...
Australian Broadcasting Corporation16h
ABC NEWS Live Stream
ABC NEWS features continuous, commercial-free coverage of major breaking stories in Australia and around the world. Watch all your favourite ABC programs on ABC iview. More from ABC We acknowledge ...